CJC-1295 With DAC is a growth peptides research compound currently in stock directly from a verified Chinese manufacturer. Every batch is HPLC-verified and shipped with a Certificate of Analysis (COA). Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino acid GHRH analogue modified with a Drug Affinity Complex — a maleimido-propionyl group that covalently binds to serum albumin via a Michael addition reaction at Cys³ of albumin. This albumin-binding technology dramatically extends the compound's plasma half-life from approximately 7 minutes (for native GHRH(1-29)) to an estimated 6-10 days, enabling infrequent administration in research protocols. The extended half-life distinguishes it sharply from CJC-1295 without DAC (also called Modified GRF 1-29), which has a half-life of approximately 30 minutes.
In rodent research models, CJC-1295 with DAC produces sustained elevation of circulating GH and IGF-1, with a pharmacokinetic profile more analogous to GH baseline elevation than the pulsatile GH release produced by short-acting GHRH analogues or GHRPs. This distinction has significant implications for research design: pulsatile versus continuous GH elevation engage different downstream signaling patterns and tissue responses. CJC-1295 with DAC is widely used in GH axis research where sustained receptor occupancy at GHRHR rather than pulsatile stimulation is the experimental requirement.
PeptidesFromChina.co supplies CJC-1295 with DAC as a lyophilized powder in sealed vials at 99%+ purity, verified by HPLC and Mass Spectrometry. Certificate of Analysis accompanies every batch. All products are for laboratory research use only and are not for human consumption.
| Chemical Class | GHRH analogue with Drug Affinity Complex (albumin-binding) |
|---|---|
| Synonyms | CJC-1295 DAC, DAC:GRF, GRF with DAC |
| Amino Acids | 30 (GHRH(1-29) backbone with DAC modification) |
| Molecular Weight | ~3459 Da |
| CAS Number | 863288-34-0 |
| Receptor Target | GHRHR (growth hormone-releasing hormone receptor) |
| Half-Life (approximate) | 6-10 days (albumin-bound) |
| Research Areas | GH axis pharmacology, sustained GHRH receptor stimulation, IGF-1 regulation, pituitary function |
| Form | Lyophilized powder |
| Storage | −20°C long-term; 2-8°C aqueous (use within 2 weeks) |
| Molecular Formula | N/A — DAC-modified 29-aa peptide; see COA |
| Sequence | Tyr-DAla-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ (+ Drug Affinity Complex) |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| CJC-1295 With DAC | 2 mg | 10 vials | ≥98% | In Stock | $94.00 |
| CJC-1295 With DAC | 5 mg | 10 vials | ≥98% | In Stock | $194.00 |
Testing method: HPLC / LC-MS. Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Certificate of Analysis (COA) is included with every order. Documentation covers purity, molecular weight, and batch identification.
CJC-1295 with DAC enables sustained GHRHR activation over days rather than minutes, producing a distinct pharmacodynamic profile compared to short-acting GHRH analogues. Research has examined how prolonged GHRHR occupancy affects GH pulse architecture, IGF-1 accumulation, and pituitary somatotroph behavior. This sustained profile is used as an experimental counterpoint to pulsatile GH secretion models in GH axis biology.
The DAC modification — maleimido-propionyl-lysine enabling covalent albumin binding — is itself a pharmacokinetic research tool. Studies examining DAC-modified compounds have contributed to understanding of albumin-binding half-life extension strategies, reaction kinetics of maleimide-thiol conjugation in vivo, and the pharmacokinetic implications of albumin as a drug carrier. CJC-1295 with DAC is a well-characterized model compound in this field.
Research protocols using CJC-1295 with DAC have examined downstream GH axis effects including IGF-1 elevation, GH-responsive tissue changes in rodent models, and pituitary feedback regulation. Its use in combination with GHRPs (GHRP-2, GHRP-6, ipamorelin) allows researchers to study synergistic GHRHR and GHS-R1a co-stimulation under conditions of prolonged versus acute GHRH receptor engagement.
CJC-1295 without DAC (Modified GRF 1-29) has a half-life of approximately 30 minutes — it stimulates a single GH pulse and is cleared rapidly. CJC-1295 with DAC binds albumin covalently, extending its half-life to 6-10 days and producing sustained GHRHR stimulation. They represent fundamentally different pharmacodynamic tools despite sharing the GHRH sequence backbone.
Yes — combining CJC-1295 with DAC (GHRHR agonist) and a GHRP such as ipamorelin, GHRP-2, or GHRP-6 (GHS-R1a agonists) is a common research design. The two receptor systems are mechanistically synergistic, and co-stimulation produces GH pulse amplification beyond what either compound achieves alone.
CJC-1295 with DAC is synthesized to 99%+ purity, verified by HPLC and Mass Spectrometry. Certificate of Analysis from the manufacturing facility is included with every batch.
The DAC is a maleimido-propionyl group attached to a lysine residue in the peptide sequence. In plasma, it reacts with cysteine-34 of serum albumin via a Michael addition, forming a stable covalent bond. The albumin-bound complex has the long circulating half-life of albumin (~19 days), significantly extending effective half-life compared to the free peptide.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.